Clinical trial
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic…
NCT00375219 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00375219 |
|---|---|
| Title | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation |
| Official title | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine. (Omacetaxine) (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia. (CML) With the T315I BCR-ABL Gene Mutation |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Collaborators | Cephalon Industry ChemGenex Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Omacetaxine mepesuccinate |
| Enrollment | 103 |
| Start date | Sep 20, 2006 |
| Primary completion | Mar 23, 2010 |
| Completion | Jun 28, 2013 |
| First posted | Sep 12, 2006 |
| Last update posted | Nov 15, 2021 |
| Countries | Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: